Key terms
About RVPH
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RVPH news
Apr 16
2:00am ET
Reviva Pharmaceuticals’ Financial Turmoil: The High Cost of Restating Finances and its Impact on Stability
Apr 15
5:12pm ET
Reviva Pharmaceuticals Advances Schizophrenia Treatment Trials
Apr 15
8:35am ET
Reviva Pharmaceuticals announces FDA alignment on brilaroxazine trial
Apr 15
8:32am ET
Reviva Pharmaceuticals: Insights from Latest SEC Report
Apr 15
8:09am ET
Reviva Pharmaceuticals announces anticipated milestones, events
Apr 15
8:07am ET
Reviva Pharmaceuticals reports 2023 EPS ($1.65), consensus ($1.63)
Mar 25
6:25am ET
Optimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic Promise
Feb 20
6:27am ET
Buy Rating Affirmed for Reviva Pharmaceuticals on Brilaroxazine’s Promise in Neuropsychiatry
Feb 06
8:17am ET
Reviva Pharmaceuticals to host KOL event to discuss data on brilaroxazine
Feb 02
4:39pm ET
Reviva Pharmaceuticals files $200M mixed securities shelf
No recent press releases are available for RVPH
RVPH Financials
Key terms
Ad Feedback
RVPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RVPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
